Drug intelligence / Profile preview

shengbaikeli

Development stage: Unknown
Lead developer: First People's Hospital of Lianyungang City
Administration: Oral

Overview

Shengbaikeli is a Traditional Chinese Medicine (TCM) granule formulation developed as a hospital preparation by The First People’s Hospital of Lianyungang. It is primarily indicated for the treatment of grade I–II leukopenia in patients with malignant tumors following antitumor therapy (chemotherapy or radiotherapy). Additionally, it is used to improve cancer-related fatigue and the overall quality of life in this patient population. As a hematopoietic stimulant, it aims to increase white blood cell counts, and its efficacy is often evaluated in comparison to other established TCM treatments like Diyushengbai Tablets.

Other names: Sheng Bai Ke Li升白颗粒Sheng-Bai Granules

Beyond the preview

Go deeper on shengbaikeli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on shengbaikeli.

Explore the full profile